Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole

Journal of Clinical Oncology

Volumn 24, Issue 19, 2006, Pages 3019-3025

  Ellis, Matthew J ^a   Tao, Yu ^b   Young, Oliver ^b   White, Sharon ^b   Proia, Alan D ^b   Murray, Julliette ^b   Renshaw, Lorna ^b   Faratian, Dana ^b   Thomas, Jeremy ^b   Dowsett, Mitch ^b   Krause, Andreas ^b   Evans, Dean B ^b   Miller, William R ^b   Dixon, J Michael ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; LETROZOLE; TAMOXIFEN; ANTINEOPLASTIC AGENT; NITRILE; TRIAZOLE DERIVATIVE; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ADJUVANT THERAPY; BREAST TUMOR; DRUG EFFECT; GENE AMPLIFICATION; GENETICS; MIDDLE AGED; PATHOPHYSIOLOGY; PROTO ONCOGENE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; GENE AMPLIFICATION; GENES, ERBB-1; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOADJUVANT THERAPY; NITRILES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TREATMENT OUTCOME; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 33745988573     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.3034     Document Type: Article

References (20)

1. Hu JC, Mokbel K: Does c-erbB2/HER2 overexpression predict adjuvant tamoxifen failure in patients with early breast cancer? Eur J Surg Oncol 27:335-337, 2001
2. Berry DA, Muss HB, Thor AD, et al: HER-2/ neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 18:3471-3479, 2000
3. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001
4. Smith IE, Dowsett M, Ebbs SR, et al: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23:5108-5116, 2005
5. Lal P, Tan LK, Chen B: Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol 123:541-546, 2005
6. Ellis MJ, Coop A, Singh B, et al: Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 63:6523-6531, 2003
7. Dowsett M, Smith IE, Ebbs SR: Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 11:951 s-958s, 2005
8. Eiermann W, Paepke S, Appfelstaedt J, et al: Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 12:1527-1532, 2001
9. Dixon JM: Role of endocrine therapy in the neoadjuvant surgical setting. Ann Surg Oncol 11: 18S-23S, 2004
10. Going JJ, Keith WN, Neilson L, et al: Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa. Gut 50:373-377, 2002
11. Tao Y, Klause A, Vickers A, et al: Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials. J Steroid Biochem Mol Biol 95:91-95, 2005
12. Dowsett M, Harper-Wynne C, Boeddinghaus I, et al: HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 61:8452-8458, 2001
13. Jain RK: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62, 2005
14. Ruohola JK, Valve EM, Karkkainen MJ, et al: Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol 149:29-40, 1999
15. Heer K, Kumar H, Read JR, et al: Serum vascular endothelial growth factor in breast cancer: Its relation with cancer type and estrogen receptor status. Clin Cancer Res 7:3491-3494, 2001
16. Dowsett M, Ebbs SR, Dixon JM, et al: Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer - A study from the IMPACT trialists. J Clin Oncol 23:2477-2492, 2005
17. Turner J, Bentey R, Tao Y, et al: Changes in tumor grade with neoadjuvant endocrine therapy: Morphological evidence for fundamental differences in the anti-tumor effects of letrozole and tamoxifen. Breast Cancer Res Treat 88:S37, 2004 (abstr 407)
18. Horobin JM, Preece PE, Dewar JA, et al: Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J Surg 78:213-217, 1991
19. Miller WR, Anderson TJ, White S, et al: Growth factor signaling in clinical breast cancer and its impact on response to conventional therapies: The Edinburgh experience. Endocr Relat Cancer 12:S119-S123, 2005 (suppl 1)
20. Viale G, Regan M, Dell'Orto P, et al: Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Presented at the 28th San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2005 (abstr 44)